Association of aberrant DNA methylation with clinicopathological features in breast cancer

By Tserga Aggeliki   Michalopoulos Nicolaos V.   Levidou Georgia   Korkolopoulou Penelope   Zografos George   Patsouris Efstratios   Saetta Angelica A.  

Oncology Reports, Vol. 27, Iss. 5, 2012-05 ,pp. : 1630-1638

Spandidos Publications

Access to resources Recommend Favorite

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy

By Foedermayr Mathilde   Sebesta Miriam   Rudas Margaretha   Berghoff Anna   Promberger Regina   Preusser Matthias   Dubsky Peter   Fitzal Florian   Gnant Michael   Steger Guenther   Weltermann Ansgar   Zielinski Christoph   Zach Otto   Bartsch Rupert  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 771-778

Springer Publishing Company

Access to resources Recommend Favorite

PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients

By Lai Yuen-Liang  

Annals of Surgical Oncology, Vol. 15, Iss. 4, 2008-04 ,pp. : 1064-1069

Springer Publishing Company

Access to resources Recommend Favorite

Aberrant promoter DNA methylation inhibits bone morphogenetic protein 2 expression and contributes to drug resistance in breast cancer

By Du Min   Su XiaoMei   Zhang Tao   Xing YongJun  

Molecular Medicine Reports, Vol. 10, Iss. 2, 2014-08 ,pp. : 1051-1055

Spandidos Publications

Access to resources Recommend Favorite

The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 139-140

Informa Healthcare

Access to resources Recommend Favorite